Effect of L-leucine therapy on hematopoietic function in elderly myelodysplastic syndrome patients

Kaori Ito, Takahiro Hayashi, Yoko Inaguma, Tomohiko Terazawa, Maiko Ando, Yosuke Ando, Masahiro Tsuge, Azusa Kato, Akane Shimato, Shinji Suzuki, Sayaka Kato, Akihiro Tomita, Shigeki Yamada, Nobuhiko Emi

研究成果: Article査読


Patients with myelodysplastic syndrome (MDS) often require blood transfusion and anticancer therapy; however, elderly patients are intolerant to the associated side effects of anticancer therapy. Because L-leucine can be used to treat Diamond–Blackfan anemia, which is caused by defects in ribosomal protein (RP) genes, resulting in increased in vivo hemoglobin synthesis, it is possible that some MDS patients who have aberrations in their RP genes could also be effectively treated with L-leucine. In the present study, we investigated the effects of L-leucine on hematopoietic function (reticulocyte count), red blood cell count, and hemoglobin level in MDS patients. We administered L-leucine (1.8g, twice daily, 3d/week) with oral vitamin B6 supplements to a final cohort of eight MDS patients for 15 (interquartile range: 11–18) weeks. We assessed the patients at 10±2 weeks after therapy initiation. Only the absolute reticulocyte count was affected, improving in 6/8 (75%) patients. The median absolute reticulocyte count was 3.5×104 (range: 2.7–6.4×104) cells/µL, an increase of 0.5×104 (range: 0.2–0.7×104) cells/µL. At 10 weeks, there was only one case of an improved hemoglobin level. Non-hematological adverse events of grade 3 were observed one raised triglycerides. These data suggest that L-leucine has little effect on MDS. However, it may contribute to the recovery of hematopoietic function, futher study be desired.

ジャーナルBiological and Pharmaceutical Bulletin
出版ステータスPublished - 2019

All Science Journal Classification (ASJC) codes

  • 薬理学
  • 薬科学


「Effect of L-leucine therapy on hematopoietic function in elderly myelodysplastic syndrome patients」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。